Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bellinger

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Science (New York, N.Y.)|October 1, 1993
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogsM A Kay, S Rothenberg, C N Landen, et al.
Journal of the American Association for Laboratory Animal Science : JAALAS|May 25, 2017
Evaluation of Anthelmintic Resistance and Exhaust Air Dust PCR as a Diagnostic Tool in Mice Enzootically Infected with <i>Aspiculuris tetraptera</i>Pratibha Kapoor, Yumiko O Hayes, Leslie T Jarrell, et al.
Artificial Cells, Blood Substitutes, and Immobilization Biotechnology|January 25, 2002
Splenic clearance mechanisms of rehydrated, lyophilized plateletsT H Fischer, E Merricks, D A Bellinger, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 9, 2002
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injuryJoseph Pye, Farhad Ardeshirpour, Arlene McCain, et al.
Human Gene Therapy|August 1, 1995
Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expressionB Fang, R C Eisensmith, H Wang, et al.
Plos One|April 3, 2014
Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigsBryan T Davis, Xiao-Jun Wang, Judy A Rohret, et al.
Human Gene Therapy|August 7, 2002
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapyRoland W Herzog, Paul A Fields, Valder R Arruda, et al.
Blood|May 15, 1993
The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia AT C Nichols, D A Bellinger, R L Reddick, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 4, 1998
von Willebrand factor does not influence atherogenesis in arteries subjected to altered shear stressT C Nichols, D A Bellinger, R L Reddick, et al.
Blood|December 25, 2015
Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVIIOscar A Marcos-Contreras, Shannon M Smith, Dwight A Bellinger, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Science (New York, N.Y.)|October 1, 1993
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogsM A Kay, S Rothenberg, C N Landen, et al.
Journal of the American Association for Laboratory Animal Science : JAALAS|May 25, 2017
Evaluation of Anthelmintic Resistance and Exhaust Air Dust PCR as a Diagnostic Tool in Mice Enzootically Infected with <i>Aspiculuris tetraptera</i>Pratibha Kapoor, Yumiko O Hayes, Leslie T Jarrell, et al.
Artificial Cells, Blood Substitutes, and Immobilization Biotechnology|January 25, 2002
Splenic clearance mechanisms of rehydrated, lyophilized plateletsT H Fischer, E Merricks, D A Bellinger, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 9, 2002
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injuryJoseph Pye, Farhad Ardeshirpour, Arlene McCain, et al.
Human Gene Therapy|August 1, 1995
Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expressionB Fang, R C Eisensmith, H Wang, et al.
Plos One|April 3, 2014
Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigsBryan T Davis, Xiao-Jun Wang, Judy A Rohret, et al.
Human Gene Therapy|August 7, 2002
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapyRoland W Herzog, Paul A Fields, Valder R Arruda, et al.
Blood|May 15, 1993
The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia AT C Nichols, D A Bellinger, R L Reddick, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 4, 1998
von Willebrand factor does not influence atherogenesis in arteries subjected to altered shear stressT C Nichols, D A Bellinger, R L Reddick, et al.
Blood|December 25, 2015
Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVIIOscar A Marcos-Contreras, Shannon M Smith, Dwight A Bellinger, et al.
Pageof 9